SBI E2-Capital

SBI Biotech is a clinical-stage biopharmaceutical company based in Japan that specializes in the discovery and development of novel immunotherapies for cancer and autoimmune diseases. As a subsidiary of SBI Holdings, the company utilizes a proprietary drug discovery platform focused on plasmacytoid dendritic cells (pDCs) and the Immunoglobulin-like transcript (ILT) receptor family. Its pipeline includes several promising candidates, most notably MEDI7734 (VIB7734), an anti-ILT7 monoclonal antibody currently in Phase 2 clinical trials for systemic lupus erythematosus. SBI Biotech also develops small molecule inhibitors targeting Toll-like receptors (TLR7/9) and monoclonal antibodies against LILRB receptors for oncology indications. The company leverages strategic partnerships with global pharmaceutical leaders, including AstraZeneca and Amgen, to advance its therapeutic programs toward commercialization.